Fig. 2
From: Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan
Remission rate after up to 52 weeks of adalimumab treatment. The proportion of patients who achieved remission with a Crohn’s Disease Activity Index (CDAI) < 150 is shown. a Remission rate of all 62 patients. b Remission rate of all 41 patients with a baseline CDAI ≥ 150. Ten patients who discontinued the study treatment were categorized into the non-remission group